<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0132">The discovery of the ‘next-generation’ anti-HIV-1 broadly neutralising antibodies (bNAbs), some of which have shown to have extraordinary potency and very wide breadth 
 <italic>in vitro</italic>, has sparked renewed interest in their potential for HIV-1 prevention and treatment through passive immunisation.
</p>
